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Abstract. irritable bowel syndrome (iBS) and gastroesopha-
geal reflux disease (GERD) overlap. It is not clear whether 
GERD is caused by non‑erosive esophagitis, or erosive esoph-
agitis. The Rome criteria are not widely used for the diagnosis 
of IBS in the clinic. In total, 1,489 IBS patients without red 
flags were included in the present retrospective study. They 
comprised of 1,331 females and 158 males with a mean age of 
51 years. The diagnosis of IBS was verified by endoscopic and 
histopathological examinations. Whereas erosive esophagitis 
occurred in 97% of patients, only 66% had GERD symptoms. 
Endoscopy and histopathological examinations revealed that 
1.4% of the IBS patients with diarrhea as the predominant 
symptom had other organic gastrointestinal diseases: 0.3% 
with celiac disease, 0.2% with Crohn's disease, 0.07% with 
ulcerative colitis, 0.6% with microscopic colitis, and 0.2% with 
colon cancer. Applying the Rome III criteria produced a sensi-
tivity of 100% [95% confidence intervals (CI)=99.8‑100.0%] 
a specificity of 98.7% (95% CI=98.0‑99.2%), a positive likeli-
hood ratio of 76.9%, and a negative likelihood ratio of 0%. 
IBS is associated with erosive esophagitis. Applying Rome III 
criteria without red flags and history, was effective in diag-
nosing IBS. Celiac disease and microscopic colitis should be 
considered as alternative diagnoses.
Introduction
Irritable bowel syndrome (IBS) is a chronic recurrent gastro-
intestinal disorder (1,2). IBS comprises two subsets: sporadic 
(nonspecific) and postinfectious (1,3). Sporadic IBS occurs 
in patients whose symptoms have been present for a long 
time without any association with gastrointestinal infections, 
while postinfectious IBS occurs in patients who experience 
the sudden onset of symptoms following a bout of gastroen-
teritis (1,3). The absence of known anatomical, physiological, 
or biochemical defects in IBS means that an IBS diagnosis is 
reached by exclusion, whereby other gastrointestinal diseases 
that can cause symptoms similar to those of IBS are ruled 
out (1‑4). Patients with IBS are therefore subjected to several 
expensive, uncomfortable, and painful examinations before a 
diagnosis can be made (1,3,4).
IBS and gastroesophageal reflux disease (GERD) are 
common disorders in the population with prevalence of 11,2, 
and 20%, respectively (1‑6). IBS and GERD overlap and 
meta‑analysis showed that the prevalence of GERD in IBS 
patients is four‑fold than in subjects without IBS (7‑16). Twins 
studies revealed that genetic factors are important in both IBS 
and GERD (12). Moreover, IBS and GERD symptoms cluster 
in families (12). It is not clear whether this overlap occurs by 
chance as these disorders are common in the population or 
because they share a common pathophysiology (17). However, 
population‑based studies showed that this overlap does not occur 
by chance (10). Whereas studies done on a large number of Asian 
IBS patients have shown that IBS overlaps with non‑erosive 
esophagitis, but not with erosive esophagitis (7,16,18), studies of 
a few European patients shown that erosive esophagitis overlaps 
with IBS and occurs in 80% of IBS patients (8,19).
Symptom‑based diagnosis criteria were introduced for 
establishing a method for the positive diagnosis of IBS, with 
the Rome IV criteria being the most recent (4,20‑26). The main 
goals of symptom‑based diagnosis are to avoid unnecessary 
expensive investigations and to facilitate the choice of treat-
ment. Rome criteria have been used extensively as inclusion 
criteria in research studies as well as in clinical pharmaco-
logical trials. However, there are several reasons why these 
criteria are not used for the diagnosis of IBS in everyday 
clinical practice (4), such as clinicians being worried about 
missing organic diseases that mimic IBS, and the complexity 
of applying the criteria (4,27). Furthermore, patients are often 
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worried of having a serious or fatal disease, and are not reas-
sured without undergoing tests and examinations to rule out 
such diseases (4).
The present retrospective study of a large number of 
European patients, which has not been done before, aimed at 
investigating the overlap of GERD with IBS and to determine 
whether IBS is associated with erosive or non‑erosive esopha-
gitis. Furthermore, it aimed at determining the probability of 
missing an organic disease when applying the Rome criteria.
Materials and methods
Patients. Patients referred to the Section for Gastroenterology, 
Stord Hospital from December 1, 2005 to December 31, 2016 
who fulfilled the Rome III criteria for the diagnosis of IBS were 
considered for inclusion in the study (26). Patients aged between 
18 and 85 years without alarm features (red flags), any organic 
gastrointestinal disease, or systemic disease were included in 
the study. The red flags include unintentional weight loss, rectal 
bleeding and/or anemia, signs of inflammation, family history 
of colorectal cancer, inflammatory bowel disease (IBD), and 
celiac disease (CD). Patients who had undergone any abdominal 
surgery were excluded, with the exception of appendectomy, 
Cesarean section, and hysterectomy.
In total, 1489 patients qualified for inclusion in the study. 
They comprised 1331 females and 158 males with a mean age of 
51 years (range 18‑82 years). Of these patients, 589 had diarrhea 
as the predominant symptom, (IBS‑D), 496 had constipation 
as the predominant symptom, and 404 had a mixture of both 
diarrhea and constipation (IBS‑M). All patients underwent a 
thorough medical history‑taking and they were asked particu-
larly about GERD symptoms. Totally, 496 patients took proton 
pump inhibitor (PPI) on demand. They were further investigated 
by blood tests, and had normal findings for the full blood count, 
inflammatory markers, electrolytes, folic acid, vitamin B12, and 
kidney, liver, and thyroid function tests.
The Regional Committee for Medical and Health Research 
Ethics West, Bergen, Norway waived the need for ethics 
approval and the need to obtain consent for the collection, 
analysis and publication of the retrospectively obtained and 
anonymized data for this non‑interventional study.
Endoscopy. All patients underwent standard gastroscopy and 
colonoscopy, which were performed by an experienced single 
gastroenterologist (MES). Gastroscopy was performed after 
an overnight fast, during which four biopsy samples were 
taken from the duodenum distal to the papilla of Vater. Patients 
used PPI were asked not to take this medication one week 
prior to gastroscopy. A routine colonoscopy was performed, 
during which two biopsies were taken from each of the cecum, 
ascending colon, transverse colon, descending colon, and 
sigmoid colon. Further biopsy samples were taken from patho-
logical findings when they were observed. The biopsy samples 
were fixed overnight in 4% buffered paraformaldehyde.
Histopathology and immunohistochemistry. The biopsy 
samples obtained from the duodenum and colon were processed 
to paraffin blocks that were cut into 5‑µm‑thick sections. The 
sections were stained with hematoxylin and eosin and immu-
nostained using the ultraView Universal DAB Detection kit 
(v.1.02.0018; Venata Medical Systems, Basel, Switzerland) and 
the BenchMark Ultra IHC/ISH staining module (Venata Medical 
Systems). They were incubated with the primary antibody for 
35 min at 37˚C. The primary antibodies used were monoclonal 
mouse antihuman leukocytes CD45 (cat. no. IS751; Dako, 
Glostrup, Denmark) and monoclonal antibodies to collagen 
type III (cat. no. P02461; Acris, Herford, Germany). CD45 is 
considered a common leukocyte antigen and is expressed exclu-
sively on cells of the hematopoietic system and their progenitors. 
The sections were examined for the possible occurrence of 
CD using Marsh's modified classification. Lymphocytic colitis 
was diagnosed in the presence of an increase in intraepithelial 
lymphocytes (>15 lymphocytes/100 epithelial cells), surface 
epithelial damage, increased lamina propria plasma cells, 
and absent or minimal crypt architectural distribution (28). 
Collagenous colitis was diagnosed when there was an increase 
or irregularity in subepithelial collagen (>10 µm) as well as the 
other inflammatory changes seen in lymphocytic colitis (28).
Statistical analysis. The difference between IBS subtypes in 
the incidence of GERD symptoms and erosive esophagitis 
were performed by Chi‑square test. Fisher's exact test was 
used for statistical analysis, and the sensitivity, specificity, 
positive and negative predictive values, and likelihood ratios 
when applying Rome III criteria were calculated. The positive 
(+LR) and negative (‑LR) likelihood ratios are calculated as 
+LR=sensitivity/1−specificity) and –LR=specificity/(1−sensi-
tivity): +LR >10 is useful for ruling IBS in and ‑LR <0.1 is 
useful for ruling IBS out (29). These analyses were performed 
using GraphPad Prism (v.7; La Jolla, CA, USA).
Results
Endoscopy and histopathology. Of the 1489 IBS patients, 
983 (66%) complained, in addition to IBS symptoms, of heart-
burn, acid regurgitation, nausea, and globus (Table I). The 
incidence of GERD symptom was higher in IBS‑C and IBS‑M 
than that in IBS‑D (Table II).
Gastroscopy revealed that of the 1489 IBS patients, 
1449 have erosive esophagitis (97%), 25 had duodenal ulcers 
(1.7%), and 9 had gastric ulcers (0.6%); the other patients 
had normal endoscopy findings. Of the patients with erosive 
esophagitis 1128 (78%) esophagitis grade A, 298 (20.4%) 
grade B and 23 (1.6%) grade C according to Los Angeles 
classification (30,31). In IBS‑D 575 (97%) patients had erosive 
esophagitis (97%). There was no difference in the incidence 
of erosive esophagitis between IBS‑D and IBS‑C (P=0.4), 
between IBS‑D and IBS‑M (P=0.9) or between IBS‑C and 
IBS‑M (P=0.5) (Table II).
The histopathological examinations of the duodenal biop-
sies showed that 15 IBS‑D patients had CD of Marsh type 1, 
1 patient had CD of Marsh type 2, and 2 patients had CD of 
Marsh type 3b. The 15 patients with CD of Marsh type 1 under-
went another gastroscopy after 3‑6 months, and new duodenal 
biopsy samples were taken and re‑examined histopathologi-
cally. Moreover, serological tests for tissue transglutaminase 
antibodies (anti‑tTG) IgA were applied to these patients. Only 
2 of the 15 original patients with Marsh type 1 CD also showed 
Marsh type 1 CD in the second duodenal biopsy samples, and 
positivity for anti‑tTG IgA (Fig. 1). The other 13 patients had 
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normal histology findings and were negative for anti‑tTG IgA. 
These five patients with CD were all females (aged 20, 24, 36, 38, 
and 60 years) and belonging to the IBS‑D subtype (Table III).
Colonoscopy examinations showed that the ileum, colon, 
and rectum were endoscopically normal in all of the IBS 
patients except for seven of those with IBS‑D (Table III). Three 
of these patients had scattered aphthoid ulcers in the mucosa 
of the terminal ileum (Fig. 2). Histopathological examinations 
confirmed the diagnosis of Crohn's disease. These patients 
were all females, and were aged 28, 32, and 59 years. The 
fourth patient had erythematous friable mucosa with loss 
of the normal vascular pattern, with this lesion including 
10 cm of the sigmoid colon and the entire rectum (Fig. 3). 
Histopathological examinations of the biopsy samples taken 
from the lesions revealed ulcerative colitis. This patient was a 
female aged 57 years. The remaining three patients each had 
a tumor in the sigmoid colon (Fig. 4), which histopathological 
examinations of the biopsy samples revealed to be adenocar-
cinomas. These patients were a female aged 58 years and two 
males aged 52 and 56 years.
Histopathological examinations of the macroscopically 
normal colon showed that two of the IBS‑D patients had 
collagenous colitis (Fig. 5) and seven IBS‑D patients had 
lymphocytic colitis. The two patients with collagenous colitis 
were males, aged 36 and 42 years, while those with lympho-
cytic colitis comprised five females and two males aged 24, 27, 
35, 36, 42, 79, and 82 years.
Applying the Rome III criteria produced a sensitivity of 
100% (95% confidence interval [CI]=99.8‑100.0%), a speci-
ficity of 98.7% (95% CI=98.0‑99.2), a positive predictive value 
of 98.7% (95% CI=98.8–99.2%), and a negative predictive 
value of 100% (95% CI=99.7‑100.0%). The LR was 74.4%. The 
calculated +LR at 76.9 and ‑LR at 0%.
Clinical data. The five patients with CD adhered to gluten‑free 
diet, but they still suffered from diarrhea, recurrent abdominal 
pain, and abdominal bloating. The histopathology findings for 
the duodenal biopsy samples taken during a new gastroscopy 
were normal.
The patients with IBD showed IBS symptoms during the 
remission period. Similarly, those patients with colon cancer 
suffered from IBS symptoms after receiving the surgical treat-
ment for their carcinoma. All patients with microscopic colitis 
(MC) became symptom‑free after receiving adequate treatment.
Discussion
Several factors contribute to the high prevalence of esopha-
gitis such as smoking, overweight, coffee drinking. However, 
the present study aimed at investigating the occurrence of 
esophagitis in an IBS population not in general population. We 
assumed that the occurrence of these factors in the IBS sample 
studied is the same as in the background population.
The present investigation is the first study of a large cohort 
of European IBS patients to establish the correlation between 
esophagitis and IBS. In the cohort of IBS patients studied here, 
the prevalence of GERD symptoms was 66%, which agrees 
well with the meta‑analysis results reported earlier (17). The 
present study showed further that the prevalence of GERD 
symptoms is higher in IBS‑C and IBS‑M than that in IBS‑D. 
Although 97% of the IBS patients in this study had erosive 
esophagitis, only 66% complained of GERD symptoms. This 
may due to that 496 of the patients (33%) took PPI on demand. 
However, 506 patients (34%) of the IBS patients included in 
the study were asymptomatic despite the esophageal lesions. It 
is also probably that IBS symptoms over shadowed the GERD 
symptoms in the asymptomatic patients. It is noteworthy that 
most of the erosive esophagitis in IBS patients were of grade 
A. Esophagitis grade A showed a high interobserver varia-
tion (32,33). However, in this study the endoscopic diagnosis 
was made by an experienced single gastroenterologist.
Table I. Gastroesophageal reflux disease symptoms in the IBS patients studied.
 Symptom observed, n
 -------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Group Heartburn Regurgitation Nausea Globus
All IBS patients 802 798 345 10
IBS‑D 205 198 2 1
IBS‑C 341 342 56 14
IBS‑M 310 298 1 0
IBS, irritable bowel syndrome; IBS‑D, IBS with diarrhea as the predominant symptom; IBS‑M, IBS with a mixture of diarrhea and constipa-
tion; IBS‑C, IBS with constipation as the predominant symptom.
Table II. Prevalence of GERD and erosive esophagitis in the 
total number of IBS patients studied and in the IBS sub‑types.
 Patients with Patients with erosive
Group GERD, n (%) esophagitis, n (%)
IBS patients total 983 (66) 14,449 (97)
IBS‑D patients 589 (55) 575 (97)
IBS‑C patients 342 (69)a 480 (97)
IBS‑M patients 320 (79)a 394 (97)
aP<0.0001 vs. IBS‑D. GERD, gastroesophageal reflux disease; IBS, 
irritable bowel syndrome; IBS‑D, IBS with diarrhea as the predominant 
symptom; IBS‑M, IBS with a mixture of diarrhea and constipation; 
IBS‑C, IBS with constipation as the predominant symptom.
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Whereas there is a general agreement that IBS overlaps 
with GERD, it is controversial as whether IBS is associated 
with non‑erosive esophagitis or with erosive esophagitis. It 
is noteworthy that studies done on a few IBS patients in the 
Western world, showed an association between erosive esoph-
agitis and IBS (8,19). In contrast, studies done on Asian IBS 
patients showed an association between IBS and non‑erosive 
esophagitis, but not with erosive esophagitis (7,18). IBS in 
Asia differs considerably from that in the Western world 
(USA and Europe). This difference includes the prevalence, 
gender predominance, clinical presentation, and probably the 
pathophysiology (34‑58). The difference between patients with 
IBS in the Western world and those in Asia may account for 
the discrepancy in the association of IBS with non‑erosive and 
erosive esophagitis.
The Rome symptom‑based criteria for the diagnosis of 
IBS have been validated in several comprehensive reviews 
Figure 1. Photomicrograph of the duodenum of a 24‑year‑old female diagnosed 
with irritable bowel syndrome based on Rome III criteria, who was found to 
suffer from celiac disease of Marsh type 1. The section was immunostained 
for CD45, which is a common leukocyte antigen and is expressed exclusively 
on cells of the hematopoietic system and their progenitors. Scale bar, 50 µm.
Figure 2. Endoscopic appearance of the terminal ileum with aphthoid ulcers 
in a 32‑year‑old female who fulfilled the Rome III criteria. A histopatho-

























































































































































































































































































































































































































































































Molecular Medicine rePorTS  20:  787-794,  2019 791
and found to have a modest specificity and reasonable sensi-
tivity (27,59‑61). The Rome criteria were recently validated by 
latent class analysis in Canadian and British cohorts comprising 
1981 and 360 IBS patients, respectively (62). In this model, the 
sensitivity in the Canadian and British cohorts were 44.7, and 
52.5%, respectively; the corresponding values for specificity 
were 85.3 and 84.3% (62), while the +LRs were 3.03 and 3.35, 
and the ‑LRs were 0.65 and 0.56 (62). In the present cohort 
of about 1 500 Norwegian IBS patients, the application of 
Rome III criteria including red flags combined with medical 
history, normal physical examination, and normal blood tests 
yielded sensitivity, specificity, +LR, and ‑LR values of 100, 
98.7, 76.9, and 0%, respectively. The Kruis scoring system for 
the diagnosis of IBS incorporated symptoms with negative 
physical findings and normal laboratory tests (63). Moreover, 
combining Rome criteria with red flags, medical history, and 
limited diagnostic tests has previously been shown to improve 
the diagnostic performance (29,59).
The gastrointestinal organic diseases whose symptoms 
overlap those of IBS and which physicians are concerned about 
missing when using symptom‑based criteria are colorectal 
cancer, CD, IBD, MC, bacterial overgrowth, and bile acid 
malabsorption (4). It has been reported that 0.02‑0.5% of 
IBS patients diagnosed using symptom‑based criteria had 
colorectal cancer, while 0.04‑4.7% had CD, 0.4‑1.9% had IBD, 
and 0.7‑1.5% had MC (1,3,4,64‑83). This means that 1.2‑8.6% 
of patients suffering from other organic diseases were misdi-
agnosed with IBS when applying symptom‑based criteria, 
which justifies the concerns of clinicians. In the present study, 
endoscopic and histopathological examinations of patients 
diagnosed using Rome III criteria revealed that 1.4% had 
another gastrointestinal organic disease: 0.2, 0.3, 0.3, and 
0.6% had colorectal cancer, CD, IBD, and MC, respectively. It 
is noteworthy that all of these patients had the IBS‑D subtype. 
Would these patients actually be missed in a clinical setting?
The patients with colorectal cancer detected in this study 
were suffering from IBS, and the IBS symptoms were the 
reason for visiting a doctor; that is, the colon cancer was found 
incidentally. All three patients were older than 50 years. The 
American College of Gastroenterology and the British Society 
of Gastroenterology recommend colonoscopies for individuals 
aged >50 years who have IBS symptoms (74,84). The CD 
and IBD patients in the present study appeared to have IBS 
in addition to their organic diseases. Typically 20‑37% of CD 
patients exhibit IBS symptoms despite adhering to a gluten‑free 
diet (85) and are believed to have IBS in addition to CD (85). 
The symptoms in these patients are triggered by the ingestion of 
wheat and wheat products, and it is difficult to conclude whether 
this is caused by gluten or by the long‑sugar‑polymer fructans in 
wheat (86). This led to the British Society of Gastroenterology 
recommending excluding CD in all patients referred with IBS, 
and to the American College of Gastroenterology advising 
excluding CD in patients with IBS‑D or IBS‑M (74,84). 
Typically 32‑39% of patients with ulcerative colitis and 42‑60% 
of patients with Crohn's disease suffer from IBS when they are in 
remission (3,76‑81). The patients with IBD in the present study 
Figure 5. Photomicrograph taken from the colon of a 42‑year‑old male who 
fulfilled the Rome III criteria. A histopathological examination revealed the 
presence of collagenous colitis. The section showed positive immunostaining 
for collagen III. Scale bar, 50 µm.
Figure 3. Photograph of the sigmoid colon taken during the colonoscopy 
of a 57‑year‑old female diagnosed with IBS based on Rome III criteria. A 
histopathological examination confirmed the diagnosis of ulcerative colitis.
Figure 4. A tumor in the sigmoid colon observed during the colonoscopy 
of a 56‑year‑old male diagnosed with irritable bowel syndrome based on 
Rome III criteria. A histopathological examination showed that the tumor 
was an adenocarcinoma.
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also suffered from IBS, and it just happened that they had active 
disease when the colonoscopies were performed. None of these 
patients would have been misdiagnosed in a clinical setting. 
In contrast, patients with MC could be misdiagnosed, and this 
group of patients should be kept in mind when symptom‑based 
criteria are used in the diagnosis of IBS, especially in IBS 
patients with diarrhea as the predominant symptom.
It is usual in clinical practice for some IBS patients to seek 
health care not because of the symptoms but due to concerns 
about possible serious or fatal underlying conditions (87,88). 
Whereas negative gastroscopy findings have been reported 
to reassure patients with functional dyspepsia and improve 
their quality of life, this did not occur for colonoscopy normal 
findings in patients with IBS (25). However, the health‑care 
provider is compelled to accommodate patients who desire 
endoscopic examinations for reassurance.
In conclusion, Rome III symptom‑based criteria with red 
flags, history, negative physical findings, and normal blood 
tests perform well in diagnosing IBS. As when applying 
other diagnostic methods in the clinic, the overall view of the 
patient should also be considered. The Rome Foundation is 
developing methods to facilitate the use of Rome criteria in 
everyday clinic practices (27). Patients who need reassurance 
by performing further examinations should be accommodated.
Because of the strong association of GERD with IBS, it 
has been recommended that physicians who encountered IBS 
patients should screen them routinely for the co‑existence of 
GERD (17). The findings of high prevalence of erosive esopha-
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